Université de Montréal

CHUM
Centre hospitalier de l'Université de Montréal

Centre universitaire de santé McGill
McGill University Health Centre

CODE VIE.CA
FONDATION DE L'HÔPITAL GÉNÉRAL DE MONTRÉAL

ELIXR 24

Early-stage Lung cancer International eXpert Retreat

Retraite d'eXperts internationaux sur le cancer du poumon à un stade précoce

June 13-14, 2024

Welcome message

Welcome to the second annual international conference entitled **Early-stage Lung cancer International eXpert Retreat - #ELIXR24**. This conference aims to bring innovative minds together to foster education and inspire discussions aimed at practical clinical management considerations and our shared desire to improve outcomes for early-stage lung cancer patients through research. It is our hope that this conference will invite open discussion on basic, translational and clinical research programs, as well as spark future research collaborations, in order to make a difference in the diagnosis and treatment of early stage lung cancer patients.

Organizing Committee Members

Dr. Normand Blais
Professor of Medicine, Université de Montréal

Dr. Jonathan Spicer
Associate Professor of Surgery, McGill University

Thank you to our sponsors

Platinum Sponsors

AstraZeneca

Bristol Myers Squibb™

MERCK

Silver Sponsors

AMGEN

REGENERON
SCIENCE TO MEDICINE®

Roche

Bronze Sponsor

Pfizer

Invited Faculty

Dr. Valsamo Anagnostou

Medical Oncologist

Johns Hopkins University, Baltimore, MD

Dr. Anagnostou is an Associate Professor of Oncology, director of the Thoracic Oncology Biorepository, leader of Precision Oncology Analytics and co-leader of the Molecular Tumor Board and the Thoracic Oncology Precision Medicine Center of Excellence in the Sidney Kimmel Cancer Center at Johns Hopkins. She graduated from Medical School of the National and Kapodistrian University of Athens, Greece and received a PhD from the same institution. After completing her internal medicine residency at Yale-New Haven Hospital, she subsequently trained in Medical Oncology at Johns Hopkins.

Dr. Anagnostou is a translational cancer investigator, focusing on large-scale genomic and liquid biopsy analyses in human cancers. Her group has discovered novel genomic mechanisms of response and resistance to immunotherapy and her research is particularly focused on understanding the molecular mechanisms of response and resistance to these therapies, capturing these by minimally invasive methods and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients. She is the international study chair of the first ctDNA-based molecular response adaptive immuno-chemotherapy clinical trial for metastatic non-small cell lung cancer (NCT04093167). Her long term goal is to transform medical oncology to personalized molecular oncology, where treatment decisions are tailored to cancer genomics and molecular real-time response assessments informed by liquid biopsies.

Dr. Mara Antonoff

Thoracic Surgeon

University of Texas MD Anderson
Cancer Center, Houston, TX

Dr. Antonoff completed her undergraduate studies at the University of Pennsylvania and earned her medical degree at the University of Minnesota, where she also completed internship and residency in General Surgery. Dr. Antonoff completed a fellowship in Cardiothoracic Surgery at Washington University in St Louis. She joined MD Anderson in 2014, where she's currently an Associate Professor of Thoracic and Cardiovascular Surgery and Program Director for Education. She is the Deputy Head of Education for Surgery.

Dr. Antonoff's research interests include pulmonary metastatic disease, early detection of lung cancer, and local consolidative therapy for stage IV lung cancer. She is the surgical lead for several trials evaluating the role of local consolidative therapy for metastatic non-small cell lung cancer. She holds several leadership roles in the STS, including chair of the STS Council on Member Engagement and its leadership Institute. She serves as the Vice President and President-Elect of the WTS. She further holds leadership roles within the AATS, the STSA, the AWS, IASLC, ESTS, and the TSDA, and Senior Editorial Board positions for Annals of Thoracic Surgery, Journal of Thoracic and Cardiovascular Surgery, Innovations, CTSNet, and Journal of Thoracic Disease.

Dr. Tina Cascone

Medical Oncologist

University of Texas MD Anderson Cancer Centre, Houston TX

Dr. Tina Cascone is an associate professor, physician-scientist in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, TX. She received her degree in medicine (summa cum laude) from the University of Campania Luigi Vanvitelli in Naples, Italy. She earned her doctorate degree in Medical and Surgical Oncology and Clinical Immunology at the same university and completed her postdoctoral studies at MD Anderson Cancer Center where she studied the impact of antiangiogenic therapy on the tumor microenvironment. She completed her residency training in internal medicine at the Barnes-Jewish Hospital/Washington University School of Medicine in St. Louis, MO, and her medical oncology fellowship at MD Anderson Cancer Center. In 2017, Dr. Cascone became an instructor in the Advanced Scholar Program at MD Anderson Cancer Center, and in 2018 joined the faculty as a tenure-track assistant professor in the Department of Thoracic/Head and Neck Medical Oncology.

Dr. Parneet Cheema

Medical Oncologist

William Osler Health

Dr. Parneet Cheema, MD, MBiotech, FRCPC, is Osler's Medical Director of Cancer Care and Head of Cancer Research. As a medical oncologist, Dr. Cheema completed her postgraduate training at the University of Toronto, where she holds an academic appointment as Assistant Professor in the Department of Medicine. Dr. Cheema is an international leader in lung cancer, precision medicine and immunotherapy treatments for cancer.

Dr. Quincy Chu

Medical Oncologist

Cross Cancer Institute, University of Alberta

Dr. Quincy Chu is a medical oncologist who specializes in thoracic malignancies as well as early phase clinical trials. He received his M.D degree from University of Toronto in Ontario, Canada. He is an investigator with the Cross Cancer Institute's New Drug Development Program, and is also the incoming CCTG Investigational New Drug Committee Chair.

Dr. Tricia Cottrell

Pathologist

Queen's University

Dr. Tricia Cottrell is a thoracic pathologist at Queen's University and a Senior Investigator with the Canadian Clinical Trials Group. She completed her MD/PhD, Anatomic Pathology Residency, and post-doctoral fellowship at Johns Hopkins University. Dr. Cottrell's research focuses on predictive biomarkers and pathologic response assessment in immunotherapy clinical trials.

Dr. Cottrell published the first characterization immune-mediated tumor regression following neoadjuvant anti-PD-1 therapy. The system is being validated as a potential standardized approach for quantifying pathologic response to neoadjuvant therapy across solid tumour types.

Mentored by Drs. Janis Taube and Alex Szalay, Dr. Cottrell is a founding member of the AstroPath platform team. The platform is a rigorously optimized and validated end to end workflow for whole slide multiplex immunofluorescence. Dr. Cottrell's lab is funded by OICR and CIHR to use AstroPath to identify predictive biomarkers in tumours from patients treated with immunotherapy, including non-small cell lung carcinoma and malignant pleural mesothelioma.

Dr. Nathalie Daaboul

Medical Oncologist

Hôpital Charles LeMoyne

Dr. Nathalie Daaboul, MD. FRCPC is a hematologist-oncologist, with an interest in thoracic malignancy. She is currently practicing at Centre Intégré de la Montérégie, Charles LeMoyne hospital. She is also an assistant professor at the Université de Sherbrooke.

Dr. Nicole Ezer

Respirologist

McGill University

Dr. Nicole Ezer's clinical research focuses on lung cancer screening, lung cancer epidemiology, comparative effectiveness, and outcomes research. Her main research interests are the application of artificial intelligence techniques to health administrative data, improving outcomes of patients screened for lung cancer, comparative effectiveness of different treatments of early-stage lung cancer, and the impact of racial and socioeconomic disparities in lung cancer management. She is also the lead clinical investigator for CONTAIN-COVID19, a clinical trial on the treatment of out patients with COVID-19.

Dr. Pierre-Olivier Fiset

Pathologist

McGill University Health Centre

Dr. Pierre-Olivier Fiset is an Anatomical Pathologist and Associate Professor at the McGill University Health Centre. His practice includes mainly Thoracic Pathology (fellowship at University of Toronto) but also Medical Kidney Pathology, Gastrointestinal Pathology and Molecular and Biomarker Pathology.

Dr. Patrick Forde

Medical Oncologist

Johns Hopkins University, Baltimore, MD

Dr. Patrick Forde treats patients with lung cancer, mesothelioma, and other thoracic cancers. He completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins. He is currently Co-Director of the Division of Upper Aerodigestive Malignancies in the Department of Oncology at Johns Hopkins and directs the multidisciplinary Thoracic Oncology Clinical Research Program.

He has led development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies. Dr. Forde's research examines the role of immunotherapy for mesothelioma and lung cancer and his work has led to the development of several ongoing phase 3 trials. In 2022, his work over several years, published in the New England Journal of Medicine, led to the FDA approval of neoadjuvant chemo-immunotherapy for the treatment of surgically operable lung cancer.

Dr. Forde serves as principal investigator for the thoracic cancer immunobiology biospecimen repository protocol at Johns Hopkins. He is focused on providing compassionate, state-of-the-art care for his patients in conjunction with a team of oncology specialist nurses, nurse practitioners, and dedicated staff.

Dr. Andrea Filippi

Radiation Oncologist

Istituto Nazionale Tumori, Milan, Italy

Dr. Filippi is the Head of the Radiation Oncology Department at Istituto Nazionale Tumori in Milan and Associate Professor of Radiotherapy at the Department of Oncology at the University of Milan.

His research and clinical interests cover new concepts for lung cancer radiotherapy and the combination of thoracic radiation and immunotherapy. PI of several clinical trials and interdisciplinary research programs directed towards developing new IO-TKI combinations and radiation technical advancements, including next-generation IGRT and radiomics.

Dr. Pierre Olivier Gaudreau

Medical Oncologist

Queen's University

Dr. Gaudreau is a medical oncologist and hematologist who completed his internal medicine, hematology and medical oncology fellowships at the University of Montreal. Following his clinical training, he completed a PhD program at the MD Anderson Cancer Center in Texas as well as the CHUM Research Center in Montreal, which featured both fundamental sciences and early clinical trials. His clinical practice at the Cancer Centre of Southeastern Ontario focuses on thoracic malignancies.

Dr. Gaudreau is an Assistant Professor at the Department of Oncology and is cross-appointed to the Department of Biomedical and Molecular Sciences at Queen's University. In addition, he is a Senior Investigator at the Canadian Cancer Trials Group for the Thoracic Oncology Site Committee and Investigational New Drug Program. His research interests include thoracic malignancies, clinical trials, investigational new drugs, translational research in thoracic oncology, mechanisms of resistance to immunotherapy, and pre-clinical models of non-small cell lung cancer.

Dr. Wael Hanna

Thoracic Surgeon
McMaster University

Dr. Hanna is the Head of Division of Thoracic Surgery at McMaster University. His research interests are clinical trials in Robotic Surgery, and the role of AI in mediastinal lymph node staging.

Dr. Rosalyn Juergens

Thoracic Medical Oncologist
McMaster University

Dr. Juergens is an Associate Professor of Oncology at McMaster University. She completed a fellowship in thoracic medical oncology at the Johns Hopkins Medical Institute as well as a Ph.D. in Clinical Investigation. She was on the faculty at Johns Hopkins from 2007-2010 until she joined the faculty at McMaster University in 2011.

Dr. Juergens' clinical expertise is in lung and esophageal cancer. Her research focus has been in developmental therapeutics with a concentration on Phase I and II clinical trials.

She chaired the Lung Disease Site Team from 2013-2023. She is also a patient advocate and serves as the Medical Advisory Committee Chair for Lung Cancer Canada. She is the Head of the Department of Clinical Trials at the Juravinski Cancer Centre. She is a member of the Escarpment Cancer Research Institute and the Centre for Discovery and Cancer Research at McMaster University. She is the past chair of the Investigational New Drug Committee of the Canadian Cancer Trial Group.

Dr. Biniam Kidane

Thoracic Surgeon

University of Manitoba

Dr. Kidane has a research interest in peri-operative care. His major interest is in lung-protective ventilation during thoracic surgery. He also has a research interest in health services and outcomes research as it relates to esophageal and lung cancer. Esophageal cancer is a devastating illness with historically poor survival; furthermore, the treatment of esophageal cancer can be difficult and cause significant reductions in the quality of life.

Dr. Kidane's program of research in esophageal cancer brings together elements of surgical quality, patient quality of life, oncologic outcomes and health resource utilization with the ultimate goal of identifying the right treatment for the right patient at the right time.

Dr. Natasha Leighl

Medical Oncologist

Princess Margaret Cancer Centre

Dr. Natasha Leighl leads the Thoracic Medical Oncology Group at the Princess Margaret Cancer Centre, and is Professor in the Department of Medicine, and Adjunct Professor in the Institute of Health Policy, Management and Evaluation at the University of Toronto. She holds the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development through the Princess Margaret Cancer Foundation. She has published over 300 peer-reviewed papers, has held (as principal or co-investigator) over $600 million in peer-reviewed grant funding, and has mentored many oncology trainees that have gone on to leadership roles in oncology around the world. Recently, she was awarded the American Society of Clinical Oncology Excellence in Teaching Award (2019).

After receiving her MD from the University of Toronto, Canada, Dr. Leighl completed residencies in internal medicine at the University of Calgary and in medical oncology at the University of Toronto. She subsequently completed a Fellowship in Thoracic Oncology with Dr. Frances Shepherd at the Princess Margaret Hospital in Canada, a Fellowship in Clinical Oncology with Prof. Martin Tattersall at the University of Sydney in Australia, and received her Masters in Medical Science (MMSc) in Clinical Epidemiology at the University of Newcastle, Australia.

Dr Leighl's main interest is in developing new treatments in lung cancer and improving lung cancer diagnostics. She is involved in clinical studies of novel agents for the treatment of thoracic cancers, has led several international and cooperative group studies in lung cancer and has served as a member of the Lung Disease Site Group Executive of the Canadian Cancer Clinical Trials Group. She was Co-Chair of the CCTG Committee on Economic Analysis, Congress Co-President of the 2018 World Conference in Lung Cancer, and serves on multiple committees including the ASCO Thoracic Guidelines Advisory Group, is co-section editor of The Oncologist and Current Oncology, an editorial board member of the Journal of Thoracic Oncology, British Journal of Cancer, a member of the IASLC Quality and Value Committee, on the Scientific Advisory Board of the Lung Cancer Foundation of America, and was recently elected to the Board of Directors of the Americas Health Foundation. Previously she served as Web Editor of the Journal of Thoracic Oncology, on the editorial board of the Journal of Clinical Oncology, the Royal College of Physicians & Surgeons of Canada Medical Oncology Examination Board, and is Past President of Lung Cancer Canada.

Dr. Magali Lecavalier-Barsoum

Radiation Oncologist

Jewish General Hospital/McGill University

After her residency in Radiation Oncology at McGill University, Dr. Lecavalier-Barsoum, did a 2-year program of combined clinical fellowship in the Radiation Medicine Program at the Princess Margaret Cancer Centre and a Master in the Institute of Medical Science, University of Toronto.

Dr. Moishe Liberman

Thoracic Surgeon

Centre Hospitalier de l'Université de Montréal

Dr. Moishe Liberman, is the Director of the CHUM Endoscopic Tracheobronchial and Esophageal Center and the inaugural Medical Director of the Multi disciplinary CHUM Robotic, Endoscopic and Minimally Invasive Surgery Program.

Dr. Liberman has ran over 60 clinical trials at the CHUM in neoadjuvant therapy, adjuvant therapy, surgical technology and novel devices.

His research interests include minimally invasive techniques for staging/ treatment of lung cancer, ultrasonographic technology in thoracic surgery, trans-oral, non-surgical techniques for lung cancer diagnosis, staging and ablation, novel methods for performing VATS lobectomy.

His research laboratory focuses on technology assessment and technology development in minimally invasive thoracic oncology, endoscopy, robotics and natural orifice surgical techniques.

Dr. Thomas Marron

Medical Oncologist

Tisch Cancer Institute, New York, NY

Thomas Marron MD PhD is the Director of the Early Phase Trials Unit at the Tisch Cancer Institute, and an Associate Professor of Medicine and an Associate Professor of Immunology and Immunotherapy.

His research focuses on development of novel immunotherapies and combinatorial therapeutic approaches for the treatment of thoracic malignancies, with an emphasis on translational studies in early-stage lung cancer.

He established The Neoadjuvant Research Group to Evaluate Therapeutics (TARGET), which is a large multidisciplinary team of clinicians and scientists tasked with defining how novel therapies work through biospecimen-heavy window-of-opportunity trials.

This program exploits novel immune monitoring platforms developed at Mount Sinai to characterize tissue, blood and stool from patients with lung cancer, enabling us to resolve the immunodynamic changes induced by standard therapies and by novel immunotherapies. Defining the determinants of spatial makeup of the tumor immune microenvironment, and resolving the complexity within the lymphoid and myeloid lineages using a variety of single-cell transcriptomic and proteomic, the aim of TARGET is to more rationally design cancer immunotherapy lung cancer trials moving forward to improve patient outcomes.

Dr. Anna McGuire

Thoracic Surgeon

Vancouver General Hospital

Dr. Anna McGuire is an active staff thoracic surgeon at Vancouver General Hospital and the University of British Columbia. Dr. McGuire is a researcher with specialty interests in lung cancer, esophageal cancer, minimally invasive surgical technology, diseases of the thymus, esophageal function and other surgical diseases of the chest.

Dr. McGuire's research focuses on lung cancer including, biomarkers, and thoracic surgical epidemiology. After graduating from the University of Toronto School of Medicine, Dr. McGuire completed general surgery residency at Queens University, thoracic surgery residency and advanced thoracic surgery fellowship at the University of Ottawa, and Master of Science in Clinical Epidemiology with the University of London (LSHTM).

Since this time, Dr. McGuire returned home to Vancouver, and has been on faculty at the University of British Columbia and Vancouver General Hospital as a Royal College of Physicians and Surgeons of Canada board certified academic thoracic surgeon.

Dr. Drew Moghanaki

Radiation Oncologist

UCLA, Los Angeles, CA

Dr. Drew Moghanaki is Professor and Chief of Thoracic Oncology in the UCLA Department of Radiation Oncology. He is co-director of the VA Greater Los Angeles Lung Precision Oncology Program and co-chair of the VALOR phase III randomized trial for operable stage I non-small cell lung cancer.

Dr. Barbara Melosky

Medical Oncologist

BC Cancer Centre

Dr. Barbara Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia.

Dr. Melosky specializes in the field of thoracic malignancies.

Dr. Melosky sits on the Executive Lung Site Committee for Canadian Clinical Trials Group (CCTG). She chairs the annual Canadian Lung Cancer Conference attended by over 450 participants, for the last 23 years.

Dr. Melosky is proud to have built the British Columbia Lung Cancer Biobank which is actively used for research for all interested.

She is published extensively and is considered a national and international expert in thoracic malignancies.

Dr. Meriem Messaoudene

Onco-Immunologist

Centre Hospitalier de l'Université de Montréal

Dr. Meriem Messaoudene is specialized in human tumor immunology since her basic training at université Pierre et Marie Curie and Institut Pasteur (Paris, France). After a PhD training program at université Paris XI in NK cells and human metastatic melanoma, she undertook a post-doctoral study on the efficiency of the new class of T cell bispecific antibodies in breast cancer at Pr. Laurence Zitvogel's lab (Institut Gustave Roussy, France) with a close collaboration to study the impact of the microbiota in the efficiency of the immune checkpoint blockades in NSCLC. Since 2018, she has started a post-doctoral at CRCHUM (Montreal, Canada) on microbiota and cancer in the new lab of Dr. Bertrand Routy with the challenge to develop new therapeutic strategies to safely increase ICB response through the manipulation of microbiota.

Dr. Isabelle Opitz

Thoracic Surgeon

Zurich Hospital University, Zurich, Switzerland

Professor Isabelle Opitz is Director of the Department of Thoracic Surgery and Chair of the Lung Cancer Center at University Hospital Zurich, Switzerland, she is Professor/Ordinaria for Thoracic Surgery at the University of Zurich.

Her clinical areas of expertise are the surgical treatment of lung cancer, pleural mesothelioma, chronic thromboembolic pulmonary hypertension, and lung transplantation.

She has received several national and international awards for her research and has acquired more than 13 million Euro grant for her own research. She is the author of more than 180 articles, including 141 original articles, multiple reviews, and book chapters. She is Past President and Past Treasurer of the European Society of Thoracic Surgeons, International Director of the American Association for Thoracic Surgery, and will be co-chair of IASLC World Conference on Lung Cancer 2025.

Dr. Cecilia Pompili

Thoracic Surgeon

University of Leeds, United Kingdom

Dr. Pompili is Associate Professor in Psychosocial Oncology and Honorary Thoracic Surgeon at University Hospital in Hull, UK. She is Visiting Associate Professor at the University of Leeds.

After completing her general thoracic surgical residency in Italy, Dr. Pompili obtained a PhD from the University of Leeds with a project investigating the Role of Patients Reported Outcomes (PROMS) In Risk Assessment and Treatment Outcomes for Early-Stage NSCLC. Her research focuses on two areas: a) patient-centred and personalised care for thoracic malignancies and b) evidence-based practice in lung cancer surgery with particular interest in risk-stratification and postoperative morbidities.

Dr. Pompili is recognized as founder of the European Society of Thoracic Surgeons (ESTS) Patient-Centred Working Group leading a European Quality of Life App project for thoracic surgical patients. She is active member of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group and ISOQOL, working on initiatives to implement PROMs in clinical practice.

She holds national and international leadership roles in the ESTS Women in General Thoracic Surgery Committee, the Society of Thoracic Surgeons, the British Thoracic Oncology Group. She has been recently elected co-chair of the IASLC Diversity and Inclusion Taskforce.

Dr. Boris Sepesi

Thoracic Surgeon

Sarah Cannon Cancer Institute
at Swedish Medical Center

Boris Sepesi, MD FACS is the Director of General Thoracic Surgery and Thoracic Surgical Oncology at the Swedish Medical Center and HCA Healthcare in Denver, CO. He has an expertise in the diagnosis and multidisciplinary management of operable NSCLC. He served as a PI or co-PI on a number of neoadjuvant clinical trials in non-small cell lung cancer, conducted collaborative translational biomarker research and authored or co-authored over 200 publications. His interests are neoadjuvant therapy , biomarker discovery, patient outcomes in NSCLC.

Dr. Stephanie Snow

Medical Oncologist

QEII Health Sciences Centre

Dr. Stephanie Snow is a staff Medical Oncologist at the QEII hospital in Halifax, Nova Scotia, treating thoracic and GI malignancies. After pursuing undergraduate training at McGill, she completed her training at Dalhousie, where she is now a full professor in the Faculty of Medicine.

Dr. Snow has a strong interest in Medical Education and is Vice Chair of the Royal College Medical Oncology Examination Board. From a research perspective she is involved in clinical research, is Associate Editor of the peer reviewed journal Current Oncology and has been widely published in prominent journals.

Finally, Dr. Snow is active in patient advocacy, serving as the current President of Lung Cancer Canada, and sits on the medical advisory committees of several other patient advocacy groups in colorectal and gastric cancer.

Dr. Masahiro Tsuboi



Thoracic Surgeon

National Cancer Center Hospital,
Kashiwa, Japan

Dr. Tsuboi is the Chief and Director of the Department of Thoracic Surgery and Oncology, the National Cancer Center Hospital East, Kashiwa, Japan. The Visiting professor of the Department of Surgery in Yokohama City and University Graduate from the school of Medicine, Yokohama, Japan.

Dr. Tsuboi is a past Board Director of International Association for the Study of Lung Cancer (IASLC), a past chair of the Lung Cancer Surgical Study Group(LCSSG) of the Japan Clinical Oncology Group(JCOG), as well as the past Board Director of World Association of Bronchology and Interventional Pulmonology (WABIP).

Dr Tsuboi is involved in numerous perioperative adjuvant and surgical clinical trials, such as JCOG0804/WJOG4507L: Sub lobar resection for small size peripheral lung adenocarcinoma, JCOG0802/WJOG4607L: Segmentectomy versus lobectomy in small-sized peripheral non-small cell lung cancer.

He has participated as principal investigator or steering committee member in several global studies in neoadjuvant/adjuvant environments, including ADAURA, Neo-ADAURA, KN-671,LIBRETTO-432, and so on.

Dr. Janis Taube



Dermapathologist

Johns Hopkins University, Baltimore, MD

Dr. Janis Taube is a professor of dermatology and pathology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. Her area of clinical expertise is dermatopathology.

Dr. Taube serves as the Director of the Division of Dermatopathology and as the Assistant Director of the Dermatoimmunology Laboratory at the School of Medicine.

Dr. Taube received her undergraduate degree in engineering from Duke University. She earned her M.D. from Tulane University and her M.Sc. in molecular medicine from University College London. She completed her residency in pathology at Johns Hopkins where she also served as the chief resident, before undertaking a dermatopathology fellowship at Stanford University. In2009, Dr. Taube returned to Johns Hopkins for her certification in the Melanoma Clinic.

She is one of the lead scientific researchers in the Department of Dermatology at Johns Hopkins. She has written over 180 peer-reviewed publications, and her research has been cited over70,000 times.

In addition to running her own research laboratory, she serves as the co-Director of the Mark Foundation Center for Advanced Genomics and Imaging and also as the co-Director of the Tumor Microenvironment Core Laboratory for the Bloomberg~Kimmel Institute for Cancer Immunotherapy.

Dr. Heather Wakelee

Medical Oncologist

Stanford Medicine

Dr. Heather Wakelee is a Professor of Medicine and Chief of the Division of Oncology at Stanford University and Deputy Director of the Stanford Cancer Institute. Dr. Wakelee serves as the Past President of the International Association for the Study of Lung Cancer (IASLC) and is a Fellow of the American Society of Clinical Oncology (FASCO). She is a graduate of Princeton University and Johns Hopkins University School of Medicine and completed her post-graduate training at Stanford University.

As an experienced lung cancer investigator, Dr. Wakelee has authored or co-authored over 300 medical articles on lung cancer and thymic malignancies and is involved in dozens of clinical trials involving adjuvant therapy, immunotherapy (particularly use of immunotherapy in the peri-operative setting for NSCLC), anti-angiogenesis agents and targeted drugs focused on many specific lung cancer subtypes defined by mutations such as EGFR, ALK, ROS1, RET, and BRAF.

Dr. Logan Walsh



Computational Cancer Biologist

Goodman Cancer Institute/McGill University

Dr. Walsh is an Associate Professor at the Goodman Cancer Institute and Department of Human Genetics at McGill University. He currently holds the Rosalind Goodman Chair in Lung Cancer Research. Dr. Walsh's lab uses spatial technology combined with artificial intelligence to help develop personalized medicine strategies for cancer patients. His recent work focuses on understanding the tumor immune microenvironment and how we can leverage spatial information to better understand cancer progression and response to therapy.

Dr. Wen-Zhao Zhong

Thoracic Surgeon

Guangdong Lung Cancer Institute, China

Dr. Wen-Zhao Zhong is the Director of Guangdong Lung Cancer Institute, and Chief Physician of Thoracic Neoplasms Surgery in Guangdong Provincial People's Hospital, Guangzhou, Guangdong Province, China.

He is the doctoral supervisor of School Of Medicine, South China University Of Technology and Southern Medical University.

He performs over 1000 minimally invasive surgeries of lung cancer per year and has undertaken four national projects supported by the National Natural Science Foundation of China.

Relevant researches have been published in Lancet Oncol, J Clin Oncol, J Thorac Oncol, Transl Lung Cancer Res, Nature Communications, NPJ Precision Oncology, Cancer, Oncologist, Lung Cancer, ATS/JVCTS/EJCTS, Ann Surg Oncol, BMC Cancer, Clin Lung Cancer and Cancer Lett.

Local Moderators Include:

- Dr. Bassam Adbulkarim
- Dr. Jason Agulnik
- Dr. Jonathan Cools-Lartigue
- Dr. Scott Owen
- Dr. Carmela Pepe
- Dr. Mathieu Rousseau
- Dr. Benjamin Shieh
- Dr. Annick Wong

Program

Day 1: Thursday June 13th, 2024

8:30 am	Breakfast and Registration	
9:30 am	Welcome message from Drs. Normand Blais and Jonathan Spicer	
Section 1: 9:45 am – 11:00 am **The state of the art in early-stage NSCLC** *Moderators: Drs. Normand Blais and Jonathan Spicer*		
9:45 am	**The Canadian landscape: ahead or behind the curve? Or maybe just right?**	Dr. Rosalyn Juergens (Juravinski Cancer Center, Hamilton, ON)
10:00 am	**Minimal residual disease detection through comprehensive analyses of circulating tumor DNA for early stage non-small cell lung cancer: *Where do we stand with clinical implementation?***	Dr. Elsa Anagnostou (Johns Hopkins University, Baltimore, MD)
10:15 am	**Who needs anti-PD(L)1 therapy in early-stage disease, and for how long?**	Dr. Tina Cascone (University of Texas MD Anderson Cancer Centre, Houston, TX)
10:30 am	**Who is resectable and how do we decide?**	Dr. Isabelle Opitz (Zurich Hospital University, Zurich, Switzerland)
10:45 am	**Augmenting RT with IO.**	Dr. Andrea Filippi (Istituto Nazionale Tumori, Milan, Italy)
11:00 am	**Cooperative group surgical trials in early-stage NSCLC: Where have we been and where are we going?**	Dr. Masahiro Tsuboi (National Cancer Center Hospital, Kashiwa, Japan)
11:15 am	**Questions and panel discussion**	
11:45 am –12:00 pm	**Refreshment Break & Exhibits**	

Bristol Myers Squib

12:00 pm **BMS Sponsored Lunch Symposium**

Navigating the Gray Zones: Integrating Neoadjuvant Immunotherapy in Resectable NSCLC Management

Drs. Rosalyn Juergens, Tina Cascone, Isabelle Opitz-Schmitt, Jonathan Spicer

Learning Objectives

- Assess the rationale for initiating neoadjuvant immunotherapy as the primary approach in resectable NSCLC management.
- Evaluate treatment objectives, including achieving pathological complete response (pCR), in resectable, non-metastatic NSCLC cases.
- Analyze the integration of immunotherapy into multidisciplinary treatment strategies, encompassing neoadjuvant, adjuvant, and perioperative settings.
- Recognize perspectives of Surgeons and Medical Oncologists regarding implementing immunotherapy interventions into individualized treatment plans for patients with resectable NSCLC.

Section 2: 1:00 pm – 2:15 pm

Pivotal science in early-stage disease

Moderators: Drs. Pierre-Olivier Fiset and Jonathan Spicer

1:00 pm	**Neoadjuvant platform studies for patients with resectable NSCLC in molecularly selected populations: current landscape and future directions.**	Dr. Pierre Olivier Gaudreau (Queen's University, Kingston, ON)
1:15 pm	**Dissecting spatial relationships within the tumor microenvironment for predictive value.**	Dr. Logan Walsh (McGill University, Montréal, QC)

1:30 pm	**Dissecting the lung microbiome as an untapped predictor of response to checkpoint blockade.**	Dr. Meriem Messaoudene (Centre Hospitalier de l'Université de Montréal, Montréal, QC)
1:45 pm	**Immunopathology in early stage. From science to clinical care.**	Dr. Tricia Cottrell (Queen's University, Kingston, ON)
2:00 pm	**Dissecting the myeloid compartment for cure.**	Dr. Thomas Marron (Tisch Cancer Institute, New York, NY)
2:15 pm – 2:30 pm	**Refreshment Break and Exhibitions**	

Section 3: 2:30 pm – 4:00 pm

What to do with the nodule?

Moderators: Drs. Bassam Abdulkarim and Jason Agulnik

2:30 pm	**Landscape of liquid diagnostics for solitary pulmonary nodules.**	Dr. Nicole Ezer (McGill University, Montréal, QC)
2:45 pm	**Blast it! And other details about diagnosis and staging for the radiation oncologist…**	Dr. Magali Lecavalier-Barsoum (McGill University, Montréal, QC)
3:00 pm	**Endobronchial surgery – from diagnostics to therapy.**	Dr. Moishe Liberman (Centre Hospitalier de l'Université de Montréal, Montréal, QC)
3:15 pm	**Is robotic surgery old-news or just the tip of the iceberg?**	Dr. Wael Hanna (McMaster University, Hamilton, ON)
3:30 pm	**Questions and panel discussion**	

Section 4: 4:00 pm – 5:30 pm

Patient centered care

Moderators: Drs. Ben Shieh and Anna McGuire

4:00 pm	**Lung cancer Canada and the unmet needs in early-stage lung cancer.**	Dr. Stephanie Snow (Dalhousie University, Halifax, NS)
4:17 pm	**Where do we stand on Patient Reported Outcomes in early-stage NSCLC?**	Dr. Cecilia Pompili (University of Leeds, United Kingdom)
4:34 pm	**Operating in black box: Lessons learned and technical accounts of operating in heavily pre-treated field.**	Dr. Mara Antonoff (University of Texas MD Anderson Cancer Center, Houston, TX)
4:51 pm	**Competing risks of recurrence versus toxicity when considering systemic therapy in early NSCLC.**	Dr. Natasha Leighl (Princess Margaret Cancer Centre, Toronto, ON)
5:08 pm	**Panel discussion**	
5:25 pm	**Closing words for Day 1**	Drs. Normand Blais and Jonathan Spicer

Day 2: Friday June 14th, 2024

Section 1: 10:30 am – 11:30

Next Generation Immunotherapy for early-stage NSCLC

Moderators: Drs. Barbara Melosky and Carmela Pepe

9: 45 am	Breakfast	
10:30 am	How to explore rational IO combinations in early-stage disease?	Dr. Patrick Forde (Johns Hopkins University, Baltimore, MD)
10:42 am	Neoadjuvant neoantigens: mRNA strategies in NSCLC.	Dr. Thomas Marron (Tisch Cancer Institute, New York, NY)
10:54 am	Same particles, different result: the new age of image-guided radiation for lung cancer.	Dr. Drew Moghanaki (UCLA, Los Angeles, CA)
11:06 am	Questions and panel discussion	

Section 2: 11:20 am -11:50 am

Global perspectives on the approach to adjuvant chemotherapy in EGFR and ALK altered resected NSCLC

Moderators: Drs. Scott Owen and Nathalie Daaboul

11:20 am	An Asian perspective on the place of chemotherapy for EGFR mutated and ALK translocated resectable NSCLC.	Dr. Wen-Zhao Zhong (Guandong Provincial People's Hospital, China)
11:30 am	A North American perspective on the place of chemotherapy for EGFR mutated and ALK translocated resectable NSCLC.	Dr. Heather Wakelee (Stanford Medicine, Stanford, CA)
11:40 am	Questions and Discussion	
11:50 am –12:00 pm	Refreshment Break & Exhibits	

12:00 pm **Merck Sponsored Lunch Symposium**

Exploring Treatment Options in Early-Stage NSCLC: Optimizing patient therapy

Drs. Natasha Leighl, Moishe Liberman and Stephanie Snow

Learning Objectives

- Review the current landscape of treatment options for early-stage NSCLC.
- Discuss the decision-making factors for peri-operative immunotherapy through patient cases.
- Share and discuss learnings around implementing new treatment options for early-stage lung cancer.

Section 3: 1:00 pm – 1:30 pm

Global perspectives on approach to surgical care in stage IA NSCLC

Moderators: Drs. Anna McGuire and Mathieu Rousseau

1:00pm	**Life after JCOG0802 when deciding on the extent of pulmonary resection for stage IA NSCLC.**	Dr. Masahiro Tsuboi (National Cancer Center Hospital, Kashiwa, Japan)
1:10 pm	**Life after CALGB140503 when deciding on the extent of pulmonary resection for stage IA NSCLC.**	Dr. Biniam Kidane (University of Manitoba, Winnipeg, MB)
1:20 pm	**Questions and Discussion**	
1:30 pm –1:45 pm	**Refreshment Break & Exhibits**	

Section 4: 1:45 pm – 2:15 pm

Treating targets in early-stage NSCLC

Moderators: Drs. Jonathan Cools-Lartigue and Bassam Abdulkarim

1:45 pm	**Early-stage ALK and EGFR altered NSCLC: Are we driving for cure or managing a chronic disease?**	Dr. Parneet Cheema (William Osler Health System, Toronto, ON)
1:55 pm	**Defining the place of anti-body drug conjugates in early-stage NSCLC.**	Dr. Quincy Chu (Cross Cancer Institute, University of Alberta, Edmonton, AB)
2:05 pm	**Challenges and opportunities with translating clinical trial science to community practice.**	Dr. Boris Sepesi (Sarah Cannon Cancer Institute at Swedish Medical Center, Englewood, CO)

Section 5: 2:15 pm – 2:45 pm

Debating choice of local therapy for locally advanced EGFR-mutated NSCLC

Moderators: Drs. Annick Wong & Jonathan Spicer

2:15 pm	**Surgery is the preferred option whenever feasible.**	Dr. Wen-Zhao Zhong (Guandong Provincial People's Hospital, China)
2:25 pm	**Chemo-radiation is the preferred option regardless of operability.**	Dr. Andrea Filippi (Istituto Nazionale Tumori, Milan, Italy)
2:35 pm	**Voting, questions and panel discussion**	
2:45 pm –3:00 pm	**Refreshment Break & Exhibits**	

Section 6: 3:00 pm – 3:30 pm

Debate #1

Closing with controversy

Debates in the temple of truth: Pathological response assessment after neoadjuvant therapy

Referees: Drs. Normand Blais and Jonathan Spicer

3:00 pm	**The IASLC pathological response assessment method should be our standard of care.**	Dr. Pierre-Olivier Fiset (McGill University, Montréal, QC)
3:10 pm	**The irPRC assessment method should be our standard of care.**	Dr. Janis Taube (Johns Hopkins University, Baltimore, MD)
3:20 pm	**Voting and discussion**	

Debate #2

Local versus systemic therapists: A new rivalry?

Referees: Drs. Normand Blais and Jonathan Spicer

3:30pm	**Total neoadjuvant therapy is feasible in early-stage NSCLC.**	Dr. Patrick Forde (Johns Hopkins University, Baltimore, MD) & Dr. Rosalyn Juergens, (Juravinski Cancer Center, Hamilton, ON)
3:40 pm	**Local therapy will always be required after neoadjuvant therapy.**	Dr. Drew Moghanaki (UCLA, Los Angeles, CA) & Dr. Mara Antonoff (University of Texas MD Anderson Cancer Center, Houston, TX)
3:50 pm	**Voting and Discussion**	
4:00 pm	**Closing remarks**	Drs. Jonathan Spicer and Normand Blais

6:00 pm **Cocktail & Dinner**

Restaurant Le Vieux Port Steakhouse
39 Rue Saint-Paul E
Montréal, QC H2Y 1G2

AstraZeneca - Dedicated to research and innovation

Committed to lung cancer care for 20 years

3 PRODUCTS – 5 INDICATIONS IN NSCLC AND 1 INDICATION IN ES-SCLC

Notice of Compliance in Canada

TAGRISSO® osimertinib tablets

January 2021

Indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA† NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

- A validated test is required to identify EGFR mutation-positive status prior to treatment.

IMFINZI® durvalumab Injection for Intravenous Use 50 mg/mL

October 2020

In combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with ES-SCLC.

TAGRISSO® osimertinib tablets

July 2018

Indicated for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations).

- A validated test is required to identify EGFR mutation-positive status prior to treatment.

IMFINZI® durvalumab Injection for Intravenous Use 50 mg/mL

May 2018

Indicated for the treatment of patients with locally advanced, unresectable, Stage III NSCLC whose disease has not progressed following platinum-based chemoradiation therapy.

TAGRISSO® osimertinib tablets

July 2016

Indicated for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR TKI therapy.

- A validated test is required to identify EGFR T790M mutation-positive status prior to treatment.

IRESSA® gefitinib tablets

December 2003

Indicated for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic NSCLC who have activating mutations of the EGFR-TK.

For more information:
Please consult the Product Monographs at www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/tagrisso-product-monograph-en.pdf, www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/imfinzi-product-monograph-en.pdf and www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/iressa-product-monograph-en.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monographs are also available by calling us at 1-800-668-6000.

EGFR=epidermal growth factor receptor; ES-SCLC=extensive-stage small cell lung cancer; NSCLC=non-small cell lung cancer; TK=tyrosine kinase; TKI=tyrosine kinase inhibitor.
† According to American Joint Committee on Cancer (7th edition)

References: 1. TAGRISSO® Product Monograph. AstraZeneca Canada Inc. January 2, 2024. **2.** TAGRISSO® Notice of Compliance. January 18, 2021. **3.** IMFINZI® Product Monograph. AstraZeneca Canada Inc. December 27, 2023. **4.** IMFINZI® Notice of Compliance. October 2, 2020. **5.** TAGRISSO® Notice of Compliance. July 10, 2018. **6.** IMFINZI® Notice of Compliance. May 4, 2018. **7.** TAGRISSO® Notice of Compliance. July 5, 2016. **8.** IRESSA® Product Monograph. AstraZeneca Canada Inc. March 31, 2021. **9.** IRESSA® Notice of Compliance. December 17, 2003.

CA-7813E
2024

AstraZeneca

TAGRISSO® osimertinib tablets

REVIEWED BY PAAB

Thank you to our Platinum Sponsor

We are in the business of breakthroughs—our diverse, promising pipeline is focused on innovative medicines that transform patients' lives. Our scientists are addressing some of the most challenging diseases of our time. We will never give up our search for more hope, for more patients, around the world.

Bristol Myers Squibb™

bms.com/ca

Thank you to our Platinum Sponsor

Helping bring renewed hope to Canadians living with cancer through our commitment to redefining what is possible

To help achieve a world where patients no longer fear a cancer diagnosis, we work to deliver innovative solutions that help improve lives and contribute to making more tomorrows possible. From the latest advancements in immuno-oncology to our pipeline of innovative medicines, we are working every day to help transform the way cancer is treated and ensure these solutions are accessible to the patients who need them most. Knowing this goes beyond medicine, we work with the entire oncology community to understand the patient journey, which is as unique and complex as cancer itself, to help address needs and remove barriers along the way. Our eyes are firmly set on the future, and through our collective passion and expertise, we believe we have what it takes to help change the course of cancer.

Thank you to our Silver Sponsors

AMGEN

REGENERON

SCIENCE TO MEDICINE®

Roche

Thank you to our Bronze Sponsor

Pfizer

Thank you to all our Partners

CHUM

Centre hospitalier
de l'Université de Montréal

Centre universitaire
de santé McGill

McGill University
Health Centre

CODE VIE.CA

FONDATION DE
L'HÔPITAL
GÉNÉRAL
DE MONTRÉAL


Université
de Montréal
McGill

ELIXR24

Early-stage Lung cancer
International eXpert Retreat

Retraite d'eXperts internationaux sur
le cancer du poumon à un stade précoce

Stay informed on ELIXR25
www.elixrconference.com